Status:
COMPLETED
HLA-B*5701 And Hypersensitivity To Abacavir
Lead Sponsor:
GlaxoSmithKline
Conditions:
HIV Infection
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective case-control study is being conducted to estimate the sensitivity of the pharmacogenetic marker, HLA-B\*5701 for hypersensitivity to abacavir (ABC HSR). The specificity of the marke...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Subjects with HIV-1 infection with clinically-suspected hypersensitivity to abacavir.
- Subjects must provide consent for skin patch testing and pharmacogenetic evaluation.
- Exclusion criteria:
- Women found to be pregnant at baseline.
- Subjects with HIV-1 infection who have tolerated abacavir for at least 12 weeks without experiencing hypersensitivity to the drug.
Exclusion
Key Trial Info
Start Date :
August 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2007
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00373945
Start Date
August 1 2006
End Date
August 1 2007
Last Update
May 18 2009
Active Locations (55)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35294
2
GSK Investigational Site
Little Rock, Arkansas, United States, 72207
3
GSK Investigational Site
Beverly Hills, California, United States, 90210
4
GSK Investigational Site
Loma Linda, California, United States, 92357